Healthcare Contract Sales Organizations Market Size, Trends, Share, Growth | Report 2022-2030
The global healthcare CSO market (contract sales organization) is anticipated to reflect a considerable growth rate across the forecast period. Healthcare CSO is a third party organization, that provides sales services to healthcare firms such as medical device companies, pharmaceutical companies, and biopharmaceutical companies on a contract basis. Adoption of new technologies for contract sales, the growing interest among end users to increase the sales of medical devices and drugs, and the surge in demand for reducing the cost associated with in-house sales are some of the key factors supporting the growth of the healthcare CSO market.
The COVID-19 pandemic, at its initial stage, severely affected the market as sales activities were not performed efficiently due to the wide spread of the virus. In the post-pandemic period, pharmaceutical and medical device companies are actively involved in conducting research. For instance, according to clinicaltrial.gov, as of November 2022, 432,718 studies were registered, whereas in 2020, 325,771 studies were reported. The clinicaltrial.gov also reports that, over 41,919 studies were in Phase 3 of clinical trials as of November 2022. This is expected to improve the number of drug launches in the coming years and thus support the demand for contract sales in the post-pandemic period.
Based on end users, the biopharmaceutical companies segment has held a significant share in the healthcare CSO market in 2022. The growing number of new biologics launches, the increase in R&D activities for biopharmaceuticals, and the increasing demand among biopharmaceutical companies to improve the over sales of their products are supporting the segment market. Moreover, there is a growing interest among biopharmaceutical companies in reducing the overall cost of in-house sales, which further promoting the demand for contract sales services.
The North America region has held a significant share in the healthcare CSO market in 2022 Growing interest among the end users in the region to outsource sales activities to an expert team to improve the overall sales performance of the company, the presence of a significant number of CSOs in the region, and increasing drug pipeline are some of the major factors supporting the growth of the North American healthcare CSO market.
The key global industry players across the healthcare CSO market includes CMIC HOLDINGS Co., LTD.; Axxelus; EPS Corporation.; QFR Solutions; MaBiCo; Mednext Pharma Private Limited; Peak Pharma Solutions Inc.; IQVIA, Inc.; Promoveo Healthl; and Syneous Health.
Market Segmentation
By Services Outlook
By End Use Outlook
By Region Outlook
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Healthcare Contract Sales Organizations Market
5.1. COVID-19 Landscape: Healthcare Contract Sales Organizations Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Healthcare Contract Sales Organizations Market, By Services
8.1. Healthcare Contract Sales Organizations Market, by Services, 2022-2030
8.1.1. Commercial services
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Non-commercial services
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Healthcare Contract Sales Organizations Market, By End Use
9.1. Healthcare Contract Sales Organizations Market, by End Use, 2022-2030
9.1.1. Pharmaceutical companies
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Biopharmaceutical companies
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Medical Device Companies
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Healthcare Contract Sales Organizations Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Services (2017-2030)
10.1.2. Market Revenue and Forecast, by End Use (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Services (2017-2030)
10.1.3.2. Market Revenue and Forecast, by End Use (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Services (2017-2030)
10.1.4.2. Market Revenue and Forecast, by End Use (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Services (2017-2030)
10.2.2. Market Revenue and Forecast, by End Use (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Services (2017-2030)
10.2.3.2. Market Revenue and Forecast, by End Use (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Services (2017-2030)
10.2.4.2. Market Revenue and Forecast, by End Use (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Services (2017-2030)
10.2.5.2. Market Revenue and Forecast, by End Use (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Services (2017-2030)
10.2.6.2. Market Revenue and Forecast, by End Use (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Services (2017-2030)
10.3.2. Market Revenue and Forecast, by End Use (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Services (2017-2030)
10.3.3.2. Market Revenue and Forecast, by End Use (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Services (2017-2030)
10.3.4.2. Market Revenue and Forecast, by End Use (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Services (2017-2030)
10.3.5.2. Market Revenue and Forecast, by End Use (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Services (2017-2030)
10.3.6.2. Market Revenue and Forecast, by End Use (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Services (2017-2030)
10.4.2. Market Revenue and Forecast, by End Use (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Services (2017-2030)
10.4.3.2. Market Revenue and Forecast, by End Use (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Services (2017-2030)
10.4.4.2. Market Revenue and Forecast, by End Use (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Services (2017-2030)
10.4.5.2. Market Revenue and Forecast, by End Use (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Services (2017-2030)
10.4.6.2. Market Revenue and Forecast, by End Use (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Services (2017-2030)
10.5.2. Market Revenue and Forecast, by End Use (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Services (2017-2030)
10.5.3.2. Market Revenue and Forecast, by End Use (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Services (2017-2030)
10.5.4.2. Market Revenue and Forecast, by End Use (2017-2030)
Chapter 11. Company Profiles
11.1. CMIC HOLDINGS Co., LTD.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Axxelus
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. EPS Corporation.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. QFR Solutions
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. MaBiCo
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Mednext Pharma Private Limited
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Peak Pharma Solutions Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. IQVIA, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Promoveo Healthl
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Syneous Health.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers